QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beconi, M. G. Articles by Lee Chiu, S.-H. Search for Related Content PubMed PubMed Citation Articles by Beconi, M. G. Articles by Lee Chiu, S.-H.

METABOLISM AND PHARMACOKINETICS OF A DIPEPTIDYL PEPTIDASE IV INHIBITOR IN RATS, DOGS, AND MONKEYS WITH SELECTIVE CARBAMOYL GLUCURONIDATION OF THE PRIMARY AMINE IN DOGS

Department of Drug Metabolism, Merck Research Laboratories, Rahway, New Jersey

The pharmacokinetics and metabolism of the L-threo isoleucine thiazolidide dipeptidyl peptidase IV inhibitor, di-[2S,3S]-2-amino-3-methyl-pentanoic-1,3-thiazolidine fumarate (ILT-threo) and its allo stereoisomer (ILT-allo) were evaluated in rats, dogs, and monkeys. Both compounds were well absorbed (>80%) in all species, and most of the dose (>60%) was recovered in urine. Metabolites identified in all species included a sulfoxide (M1), a sulfone (M2), and a carbamoyl glucuronide (M3). For both compounds, parent drug had moderate systemic clearance in rats and dogs (20–35 ml/min/kg in both species) and lower clearance in monkeys (6–9 ml/min/kg). In rats, M1 was present in systemic circulation in concentrations similar to that of parent drug, whereas in dogs and monkeys, exposures to M1 were higher than for parent drug. In dogs, exposures to the sulfoxide metabolite were 2 to 3 times higher after administration of ILT-allo than after administration of ILT-threo. Carbamoyl glucuronidation was an important biotransformation pathway in dogs. Circulating levels of M3 were significant in the dog, and present only in trace levels in rats and monkeys. M3 could be produced in in vitro systems in a NaHCO₃ buffer under a CO₂-saturated atmosphere and in the presence of UDP-glucuronic acid and alamethicin.

This article has been cited by other articles:

				C. Li, M. Kuchimanchi, D. Hickman, L. Poppe, M. Hayashi, Y. Zhou, R. Subramanian, G. Kumar, and S. Surapaneni In Vitro Metabolism of the Novel, Highly Selective Oral Angiogenesis Inhibitor Motesanib Diphosphate in Preclinical Species and in Humans Drug Metab. Dispos., July 1, 2009; 37(7): 1378 - 1394. [Abstract] [Full Text] [PDF]

				M. G. Beconi, J. R. Reed, Y. Teffera, Y.-Q. Xia, C. J. Kochansky, D. Q. Liu, S. Xu, C. S. Elmore, S. Ciccotto, D. F. Hora, et al. Disposition of the Dipeptidyl Peptidase 4 Inhibitor Sitagliptin in Rats and Dogs Drug Metab. Dispos., April 1, 2007; 35(4): 525 - 532. [Abstract] [Full Text] [PDF]

				C. L. Shaffer, M. Gunduz, T. N. O'Connell, R. S. Obach, and S. Yee BIOTRANSFORMATION OF A GABAA RECEPTOR PARTIAL AGONIST IN SPRAGUE-DAWLEY RATS AND CYNOMOLGUS MONKEYS: IDENTIFICATION OF TWO UNIQUE N-CARBAMOYL METABOLITES Drug Metab. Dispos., November 1, 2005; 33(11): 1688 - 1699. [Abstract] [Full Text] [PDF]

				G. R. Lankas, B. Leiting, R. S. Roy, G. J. Eiermann, M. G. Beconi, T. Biftu, C.-C. Chan, S. Edmondson, W. P. Feeney, H. He, et al. Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes: Potential Importance of Selectivity Over Dipeptidyl Peptidases 8 and 9 Diabetes, October 1, 2005; 54(10): 2988 - 2994. [Abstract] [Full Text] [PDF]

				M. Foltz, A. Meyer, S. Theis, H.-U. Demuth, and H. Daniel A Rapid in Vitro Screening for Delivery of Peptide-Derived Peptidase Inhibitors as Potential Drug Candidates via Epithelial Peptide Transporters J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 695 - 702. [Abstract] [Full Text] [PDF]